EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Recent and anticipated novel drug approvals for 2024

Matthew H Rim, Brittany L Karas, Farah Barada, Andrew M Levitsky

American Journal of Health-System Pharmacy · 2024

DOI: 10.1093/ajhp/zxae046 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift American Journal of Health-System Pharmacy, 2024. Verfasst von Matthew H Rim und 3 weiteren Autor:innen. Beteiligte Einrichtung: Northwestern Medicine, Chicago, IL, USA. Hauptthemen laut MEDLINE: Drug Approval, United States Food and Drug Administration. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 14 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Health-system pharmacists play a crucial role in monitoring the pharmaceutical pipeline to manage formularies, allocate resources, and optimize clinical programs for new therapies. This article aims to support pharmacists by providing periodic updates on new and anticipated novel drug approvals. Summary Selected drug approvals anticipated in the 12-month period covering the first quarter of 2024 through the fourth quarter of 2024 are reviewed. The analysis emphasizes drugs expected to have significant clinical and financial impact in hospitals and clinics, as selected from 59 novel drugs awaiting US Food and Drug Administration approval. This year’s pipeline includes recently added drugs with various indications including oncology, infectious diseases, genetic disorders, and rare diseases. New cellular and gene therapies are rapidly evolving and being studied for several rare diseases and cancers.

Conclusion

More oncology agents, including gene therapies, oral agents, and monoclonal antibodies, are in the pipeline this year. Additional diseases targeted by new novel drugs, including cellular and gene therapies, are hemophilia, nonalcoholic steatohepatitis, Alzheimer’s disease, and rare diseases such as galactosemia and epidermolysis bullosa.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug ApprovalUnited States Food and Drug AdministrationHumansUnited StatesPharmacistsAntineoplastic Agents

Stichwörter der Autor:innen

Food and Drug Administration drug approvalclinical trialsdrug approval processinvestigational drugsmedication developmentnew drug approvals

Substanzen

Antineoplastic Agents

Autor:innen und Institutionen

  • Northwestern Medicine, Chicago, IL, USA.
  • IPD Analytics, Aventura, FL, USA.

Zitieren

APA

Rim, M. H., Karas, B. L., Barada, F., & Levitsky, A. M. (2024). Recent and anticipated novel drug approvals for 2024. American Journal of Health-System Pharmacy. https://doi.org/10.1093/ajhp/zxae046

Vancouver

Rim MH, Karas BL, Barada F, Levitsky AM. Recent and anticipated novel drug approvals for 2024. American Journal of Health-System Pharmacy. 2024. doi:10.1093/ajhp/zxae046

BibTeX
@article{Rim2024,
  author = {Rim, Matthew H and Karas, Brittany L and Barada, Farah and Levitsky, Andrew M},
  title = {Recent and anticipated novel drug approvals for 2024},
  journal = {American Journal of Health-System Pharmacy},
  year = {2024},
  doi = {10.1093/ajhp/zxae046}
}
Kostenlos starten →